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We appreciate the contribution of Drs. Shrader
and her colleagues for their case report that
observed an increase in warfarin’s therapeutic
effect when a patient began receiving
azithromycin.1 The authors addressed two key
factors that they felt had changed from when
warfarin activity was relatively stable
(international normalized ratios [INRs] ranging
from 1.75–3.03 during the previous 3 mo) to
when the INR increased dramatically to 8.32.
The first factor was the addition of azithromycin
for treatment of an upper respiratory tract
infection; the second was a decline in cigarette
smoking from 1 pack/day to 1 pack every 3 days.
We feel that there may have been one other factor
that could have accounted for, or at least
contributed to, the increase in INR.  Specifically,
the infectious process itself may have had an
effect on the functioning of the hepatic
isoenzymes that are responsible for warfarin’s
biotransformation.
Several researchers have documented a
decrease in hepatic cytochrome P450 (CYP)
isoenzyme activity in relation to various types of
infections.  A review article examined the
available literature concerning the effects of
inflammation and infection on drug metabolism
through CYP isoenzymes.2 It is now understood
that infection and inflammation may have
varying effects on concentrations of drugs that
are metabolized hepatically by these isoenzymes.
For example, it is known that influenza virus
infection can cause an elevation in the plasma
concentration of theophylline, sometimes leading
to toxic levels.2–4 In addition, decreased anti-
pyrine clearance was observed in 14 patients
when they developed fever and pneumonia
(likely secondary to a bacterial infection)
compared with when they were healthy.5 Based
on the historic utility of antipyrine as a
determinant of hepatic CYP activity, this study
served as an important progenitor for future
research.
Currently, it is believed that the substances
released during inflammation and infection elicit
a downregulation of CYP isoenzymes.  Whereas
production of cytokines such as interleukins,
glucocorticoids, and tumor necrosis factors is
implicit in all cases of infection, specific
responses may depend on the type of biologic
process.  For example, lipopolysaccharide
production in gram-negative bacterial infections
has been shown to cause decreased concentrations
of CYP enzymes, and this effect is accompanied
by reduced drug clearance.2, 6 In addition,
interferon production has been implicated as a
likely factor in viral infections. The decrease in
CYP enzyme activity has often been accompanied
by a decrease in messenger RNA in the liver,
suggesting that inflammation and infection may
somehow result in a selective decrease in gene
expression.2–4
Unfortunately, we could not find any published
literature that directly investigated the effects of
infection on warfarin disposition.  In addition,
most of the evidence available on this subject
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ALTERNATIVE VIEWPOINTS  Eschenauer et al
dealt with animals, not in vivo human data.  As
such, more research is necessary to elucidate the
specific effects of infection and inflammation on
drug metabolism in humans in the clinical
setting.
Hypoprothrombinemic interactions between
warfarin and numerous antiinfectives are well
documented, clinically evident, and involve
several different mechanisms.  In their review, Dr.
Shrader and colleagues described warfarin-
antibiotic interactions involving altered intestinal
flora, hepatic enzyme inhibition, and competition
for protein binding.1 In addition, there is
evidence that a fourth type of interaction
involving methylthiotetrazole side-chain–
containing cephalosporins such as cefotetan may
also be clinically relevant in some settings.7
Finally, we wish to discuss another mechanism
of warfarin potentiation interaction, whereby
inflammatory cytokines themselves may be the
culprits in slowing the metabolism of the
anticoagulant.  This could be the very mecha-
nism that has led to increased INRs with warfarin
in patients taking levofloxacin, an antibiotic that,
like azithromycin, has not been found to alter the
function of CYP isoenzymes in in vitro studies.
Indeed, whereas case reports have implied that a
levofloxacin-warfarin interaction may exist,8, 9
one pharmacokinetic study done in young
healthy volunteers showed no pharmacokinetic
interaction between levofloxacin and warfarin.10
Of course, just as was done with research on the
ciprofloxacin-warfarin interaction,11 more studies
should be conducted on older, more debilitated
patients to better determine the nature and
significance of the levofloxacin-warfarin inter-
action in clinical practice.  Now the same appears
to be true with azithromycin’s effect on warfarin.
Dr. Shrader and colleagues1 stated that their
case was the first documented report of an
interaction between azithromycin and warfarin
with very little chance of other confounders
being present.  We offer another consideration
for clinicians:  some antibiotics may play the role
of “red herrings” in the “what caused potentiation
of warfarin?” game.  However, just as the authors
recommended routine monitoring of prothrombin
time and INR when patients are receiving
concomitant azithromycin and warfarin, we feel
that any patient receiving warfarin should be
monitored more closely whenever an infection is
identified, regardless of the antibiotic(s) chosen
to treat that infection.
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Authors’ Reply
The comments provided by Dr. Eschenauer
and his colleagues in response to our case report1
describing a potential interaction between
azithromycin and warfarin are interesting.  We do
agree that it is unfortunate that no literature can
be found that directly investigates the effects of
infection on warfarin disposition.  The
hypothesis suggesting that an infectious process
may alter the anticoagulant response warrants
further investigation.  Perhaps one does need to
be mindful of the hepatic cytochrome P450
isoenzyme activity in response to the infectious
process.  As we concluded in our case report,
patients prescribed azithromycin should receive
close monitoring of the anticoagulant response.
Sarah P. Shrader, Pharm.D.
Joli D. Fermo, Pharm.D.
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